Msci Inc (MSCI) Stock Price Today
Replimune's melanoma drug gets FDA nod but faces legal probe over data practices
Replimune Group's melanoma drug Tudriqev received accelerated FDA approval after two prior rejections, based on a 24.20% response rate in trials. Following this, BMO Capital raised its price target for Replimune stock from $16 to $20, indicating stro...
Digital Realty backs Texas Governor Abbott's plan for responsible data center growth amid rising AI demand.
Digital Realty, the largest cloud- and carrier-neutral data center platform, supports Texas Governor Abbott's initiative for responsible and transparent data center investment in Texas. The company emphasizes collaboration with officials and communit...
Verisk Analytics CEO Lee Shavel sells 2,500 shares for $550,000.
Verisk Analytics CEO Lee Shavel has sold 2,500 shares of the company, generating $550,000 from the transaction. This sale may indicate personal portfolio adjustments or strategic financial planning by the CEO. Investors might watch for any further in...
Replimune's stock jumps after FDA approves its first skin cancer drug Tudriqev
Replimune Group Inc. received FDA approval for Tudriqev, its first drug targeting a difficult form of skin cancer, marking a major milestone for the biotech company. Despite earlier rejections and concerns over clinical data quality, the FDA granted ...
Crude oil prices remain volatile amid geopolitical tensions around the Strait of Hormuz.
Crude oil markets experienced significant volatility this week due to ongoing geopolitical tensions between Washington and Tehran, particularly involving the Strait of Hormuz. Prices for WTI crude hovered near key support at $70 and resistance around...
Markets jittery after weak job growth and Honeywell Aerospace's poor earnings hit shares.
Markets showed early gains following a surprise jobs report indicating softer job growth, which reduces the likelihood of further interest rate hikes. However, the positive momentum may be short-lived as it coincides with a typically slow summer trad...
Core Scientific rated Buy on strong colocation revenue and AI market growth, with 93% stock upside potential.
Core Scientific's colocation business, which makes up over 80% of its revenue, is driving strong financial performance supported by long-term contracts with clients like AMD and CoreWeave. The company is expected to see significant revenue growth, wi...
Warner Bros. Discovery revenue drops 11.3% amid merger delays and weak fundamentals
Warner Bros. Discovery reported an 11.3% revenue decline in Q2 2026, driven by sharp drops in content and advertising revenues. Despite some resilience in earnings per share and EBITDA, the company's outlook remains weak due to deteriorating business...
Man Group PLC discloses 0.57% stake in Bodycote Plc, reducing long equity swap positions.
Man Group PLC has publicly disclosed holding a 0.57% interest in Bodycote Plc as of August 6, 2026. The disclosure reveals that Man Group is reducing its long positions through multiple equity swap transactions at varying prices. This update is part ...
Amylyx shifts focus to endocrine drug avexitide with strong cash runway into 2028 and key trial results in 2026
Amylyx Pharmaceuticals is transitioning from its previous focus on ALS treatments to developing avexitide, a late-stage endocrine drug targeting post-bariatric hypoglycemia, a large orphan market with no approved therapies. The company has $250.8 mil...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.